TY  - CONF
AU  - Ćulafić, Milica
AU  - Đorđević, J.
AU  - Stanković, Sanja
AU  - Štulić, Miloš
AU  - Pejić, Nina
AU  - Vezmar-Kovačević, Sandra
AU  - Oluić, Branislav
AU  - Miljković, Branislava
AU  - Ćulafić, Đorđe
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4337
PB  - Elsevier B.V.
C3  - Clinica Chimica Acta
T1  - Adverse drug reactions of tacrolimus after liver transplant - Our Experience
VL  - 530
IS  - Supplement 1
SP  - S448
EP  - S448
DO  - doi.org/10.1016/j.cca.2022.04.395
ER  - 

@conference{
author = "Ćulafić, Milica and Đorđević, J. and Stanković, Sanja and Štulić, Miloš and Pejić, Nina and Vezmar-Kovačević, Sandra and Oluić, Branislav and Miljković, Branislava and Ćulafić, Đorđe",
year = "2022",
publisher = "Elsevier B.V.",
journal = "Clinica Chimica Acta",
title = "Adverse drug reactions of tacrolimus after liver transplant - Our Experience",
volume = "530",
number = "Supplement 1",
pages = "S448-S448",
doi = "doi.org/10.1016/j.cca.2022.04.395"
}

Ćulafić, M., Đorđević, J., Stanković, S., Štulić, M., Pejić, N., Vezmar-Kovačević, S., Oluić, B., Miljković, B.,& Ćulafić, Đ.. (2022). Adverse drug reactions of tacrolimus after liver transplant - Our Experience. in Clinica Chimica Acta
Elsevier B.V.., 530(Supplement 1), S448-S448.
https://doi.org/doi.org/10.1016/j.cca.2022.04.395

Ćulafić M, Đorđević J, Stanković S, Štulić M, Pejić N, Vezmar-Kovačević S, Oluić B, Miljković B, Ćulafić Đ. Adverse drug reactions of tacrolimus after liver transplant - Our Experience. in Clinica Chimica Acta. 2022;530(Supplement 1):S448-S448.
doi:doi.org/10.1016/j.cca.2022.04.395 .

Ćulafić, Milica, Đorđević, J., Stanković, Sanja, Štulić, Miloš, Pejić, Nina, Vezmar-Kovačević, Sandra, Oluić, Branislav, Miljković, Branislava, Ćulafić, Đorđe, "Adverse drug reactions of tacrolimus after liver transplant - Our Experience" in Clinica Chimica Acta, 530, no. Supplement 1 (2022):S448-S448,
https://doi.org/doi.org/10.1016/j.cca.2022.04.395 . .

TY  - CONF
AU  - Marinković, Valentina
AU  - Bekcić, Stana
AU  - Đorđević, J.
AU  - Tasić, Ljiljana
AU  - Stojković, Tatjana
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2682
AB  - Objectives: To assess current attitudes of urologists to „off-label“ prescribing
of BCG vaccine for high grade non-muscle invasive bladder cancer (NMIBC) and
carcinoma-in-situ (CIS), as well as to perform a pharmacoeconomic evaluation
of BCG vaccine manufactured by local pharmaceutical company. Methods: The
attitudes and experiences of urologists regarding „off-label“ use of BCG vaccine
for intravesical immunotherapy of bladder cancer, have been evaluated by using
non-probability snowball sampling technique and specifically designed question-
naire. Clinical, social, economic, ethical and regulatory factors have been included.
Snowball sampling has involved urologists from ten different hospitals in the
Northern, Central and Southern Serbia, greatly experienced in intravesical BCG
immunotherapy. Results: BCG is used for intravesical immunotherapy, and has
become the standard care for NMIBC and CIS. BCG therapy may reduce the risk of
tumour progression, appearing to be better in preventing recurrences compared to
chemotherapy, but with significantly more side effects. „Off-label“ use is the use
of a medicinal product for another indication, another patient group, another dose
or by another route of administration as indicated in the package insert. It was
noted that BCG was in the „off-label” use in a 50,0% hospitals which had a problem
with purchase of BCG for immunotherapy (regarding worldwide shortages). It was
estimated that there were 1095 patients with bladder cancer in Serbia per year. The
model according to which 18 vials of domestic BCG vaccine are used for immu-
notherapy per patient per year, projected the net budget savings of 593 862.30 € per year. Conclusions: This research could support the further clinical studies
of BCG vaccine of local manufacturer, for new indications (NMIBC and CIS). That
would enable lower costs per patient, higher quality, availability and the continuous
supply of immunotherapy.
PB  - Elsevier Science Inc
C3  - Value in Health
T1  - A prospective assesment of attitudes and experiences among urologists regarding off label use of bcg vaccine in Serbia
VL  - 19
IS  - 7
SP  - A497
EP  - A498
DO  - 10.1016/j.jval.2016.09.875
ER  - 

@conference{
author = "Marinković, Valentina and Bekcić, Stana and Đorđević, J. and Tasić, Ljiljana and Stojković, Tatjana",
year = "2016",
abstract = "Objectives: To assess current attitudes of urologists to „off-label“ prescribing
of BCG vaccine for high grade non-muscle invasive bladder cancer (NMIBC) and
carcinoma-in-situ (CIS), as well as to perform a pharmacoeconomic evaluation
of BCG vaccine manufactured by local pharmaceutical company. Methods: The
attitudes and experiences of urologists regarding „off-label“ use of BCG vaccine
for intravesical immunotherapy of bladder cancer, have been evaluated by using
non-probability snowball sampling technique and specifically designed question-
naire. Clinical, social, economic, ethical and regulatory factors have been included.
Snowball sampling has involved urologists from ten different hospitals in the
Northern, Central and Southern Serbia, greatly experienced in intravesical BCG
immunotherapy. Results: BCG is used for intravesical immunotherapy, and has
become the standard care for NMIBC and CIS. BCG therapy may reduce the risk of
tumour progression, appearing to be better in preventing recurrences compared to
chemotherapy, but with significantly more side effects. „Off-label“ use is the use
of a medicinal product for another indication, another patient group, another dose
or by another route of administration as indicated in the package insert. It was
noted that BCG was in the „off-label” use in a 50,0% hospitals which had a problem
with purchase of BCG for immunotherapy (regarding worldwide shortages). It was
estimated that there were 1095 patients with bladder cancer in Serbia per year. The
model according to which 18 vials of domestic BCG vaccine are used for immu-
notherapy per patient per year, projected the net budget savings of 593 862.30 € per year. Conclusions: This research could support the further clinical studies
of BCG vaccine of local manufacturer, for new indications (NMIBC and CIS). That
would enable lower costs per patient, higher quality, availability and the continuous
supply of immunotherapy.",
publisher = "Elsevier Science Inc",
journal = "Value in Health",
title = "A prospective assesment of attitudes and experiences among urologists regarding off label use of bcg vaccine in Serbia",
volume = "19",
number = "7",
pages = "A497-A498",
doi = "10.1016/j.jval.2016.09.875"
}

Marinković, V., Bekcić, S., Đorđević, J., Tasić, L.,& Stojković, T.. (2016). A prospective assesment of attitudes and experiences among urologists regarding off label use of bcg vaccine in Serbia. in Value in Health
Elsevier Science Inc., 19(7), A497-A498.
https://doi.org/10.1016/j.jval.2016.09.875

Marinković V, Bekcić S, Đorđević J, Tasić L, Stojković T. A prospective assesment of attitudes and experiences among urologists regarding off label use of bcg vaccine in Serbia. in Value in Health. 2016;19(7):A497-A498.
doi:10.1016/j.jval.2016.09.875 .

Marinković, Valentina, Bekcić, Stana, Đorđević, J., Tasić, Ljiljana, Stojković, Tatjana, "A prospective assesment of attitudes and experiences among urologists regarding off label use of bcg vaccine in Serbia" in Value in Health, 19, no. 7 (2016):A497-A498,
https://doi.org/10.1016/j.jval.2016.09.875 . .

TY  - CONF
AU  - Đorđević, J.
AU  - Mitrović, M.
AU  - Marinković, Valentina
AU  - Tasić, Ljiljana
AU  - Krajnović, Dušanka
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2109
AB  - Objectives: Colistimethate sodium (Colistin) is an old, “forgotten” antibiotics
revived due to multidrug-resistant Gram-negative bacteria in nosocomial infec-
tions. In many countries, both – intravenous and inhalational administrations of
Colistin have marketing authorisation. In Serbia, Colistin is registered only for
intravenous administration. Therefore, inhalational administration of Colistin in
treatment for cystic fibrosis is considered as off label use. AiM: The purpose of
this study was to assess benefits of Colistin off label use, currently available in
Serbia, for treatment for cystic fibrosis. MethOds: Data collected from a review
of the literature (Pubmed searching key word off label, Colistin, Tobramycine, cost
minimisation) and data from Health Insurance Fond of Republic Serbia (2014)
were used to perform a cost-minimisation analysis comparing DDD in inhalation
administration of Colistin with Tobramycin (official methodology in Serbia for drug
reimbursement Listing). Results: Both, Colistin and Tobramycine are effective
in cystic fibrosis treatment. The cost of treatment per patient per year in Serbia is
3 616,00 Euro for Colistin and 5 950,00 Euro for Tobramycin. Total savings per year
for 200 registered patients in Serbia could be 466 857,00 Euro. cOnclusiOns:
Given cost-minimisation analysis justified the treatment with Colistin as cost
saving therapeutic alternative to Tobramycin for cystic fibrosis patients in Serbia.
The lack of guidelines and principles regarding off label medicine use in health
care policy and decision making in Serbia was evidently an obstacle for better
patients care.
PB  - Elsevier Science Inc
C3  - Value in Health
T1  - Cost-Minimisation Analysis of Colistimethate Sodium in Serbia- off Label Use Approach
VL  - 17
IS  - 7
SP  - A399
EP  - A399
DO  - 10.1016/j.jval.2014.08.904
ER  - 

@conference{
author = "Đorđević, J. and Mitrović, M. and Marinković, Valentina and Tasić, Ljiljana and Krajnović, Dušanka",
year = "2014",
abstract = "Objectives: Colistimethate sodium (Colistin) is an old, “forgotten” antibiotics
revived due to multidrug-resistant Gram-negative bacteria in nosocomial infec-
tions. In many countries, both – intravenous and inhalational administrations of
Colistin have marketing authorisation. In Serbia, Colistin is registered only for
intravenous administration. Therefore, inhalational administration of Colistin in
treatment for cystic fibrosis is considered as off label use. AiM: The purpose of
this study was to assess benefits of Colistin off label use, currently available in
Serbia, for treatment for cystic fibrosis. MethOds: Data collected from a review
of the literature (Pubmed searching key word off label, Colistin, Tobramycine, cost
minimisation) and data from Health Insurance Fond of Republic Serbia (2014)
were used to perform a cost-minimisation analysis comparing DDD in inhalation
administration of Colistin with Tobramycin (official methodology in Serbia for drug
reimbursement Listing). Results: Both, Colistin and Tobramycine are effective
in cystic fibrosis treatment. The cost of treatment per patient per year in Serbia is
3 616,00 Euro for Colistin and 5 950,00 Euro for Tobramycin. Total savings per year
for 200 registered patients in Serbia could be 466 857,00 Euro. cOnclusiOns:
Given cost-minimisation analysis justified the treatment with Colistin as cost
saving therapeutic alternative to Tobramycin for cystic fibrosis patients in Serbia.
The lack of guidelines and principles regarding off label medicine use in health
care policy and decision making in Serbia was evidently an obstacle for better
patients care.",
publisher = "Elsevier Science Inc",
journal = "Value in Health",
title = "Cost-Minimisation Analysis of Colistimethate Sodium in Serbia- off Label Use Approach",
volume = "17",
number = "7",
pages = "A399-A399",
doi = "10.1016/j.jval.2014.08.904"
}

Đorđević, J., Mitrović, M., Marinković, V., Tasić, L.,& Krajnović, D.. (2014). Cost-Minimisation Analysis of Colistimethate Sodium in Serbia- off Label Use Approach. in Value in Health
Elsevier Science Inc., 17(7), A399-A399.
https://doi.org/10.1016/j.jval.2014.08.904

Đorđević J, Mitrović M, Marinković V, Tasić L, Krajnović D. Cost-Minimisation Analysis of Colistimethate Sodium in Serbia- off Label Use Approach. in Value in Health. 2014;17(7):A399-A399.
doi:10.1016/j.jval.2014.08.904 .

Đorđević, J., Mitrović, M., Marinković, Valentina, Tasić, Ljiljana, Krajnović, Dušanka, "Cost-Minimisation Analysis of Colistimethate Sodium in Serbia- off Label Use Approach" in Value in Health, 17, no. 7 (2014):A399-A399,
https://doi.org/10.1016/j.jval.2014.08.904 . .

TY  - CONF
AU  - Arsić, J.
AU  - Krajnović, Dušanka
AU  - Tasić, Ljiljana
AU  - Marinković, Valentina
AU  - Đorđević, J.
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2112
AB  - Objectives: The lack of information and scientific knowledge of rare diseases (RDs)
and orphan drug (ODs) could affect the quality of health care delivered to patients suf-
fering from rare diseases. The aim of this study was evaluation of the level of the general
epidemiological knowledge among pharmacists regarding RDs and ODs as well as how
that knowledge is influenced by information sources, education level and years of expe-
rience. MethOds: The research design was based on a descriptive cross-sectional study.
A questionnaire previously used in a pilot KAP study in Serbiain2012 was applied. The
respondents were 182 pharmacists from public pharmacies in seven of 29 districts in
Serbia. Individual level of knowledge was assessed by total number of correct answers
from a maximum of 9, and overall knowledge was an average of the individual level of
knowledge. Results: In total, 155 pharmacists were included in the full analysis set
(response rate was 86.3%). Overall, the mean age was 43.4 years, and 94% were women.
The average number of information sources regarding RD was 1.7%, and mostly one
source out of five was used (56.1%). Pharmacists who were engaged in post-graduate
programmes or completed such programmes tended to use more sources of information
(69.2%) than those who were not involved in any such programme (41.9%). The mean
value of correct answers about pharmacists’ knowledge regarding RD and OD was 4 ±
1.77. Most pharmacists (n = 30, 19.35%) replied correctly to 6 questions. cOnclusiOns:
The results indicate that years of experience and age among pharmacists do not have
influence to the overall knowledge about RD. The positive impact of education was evi-
dently, and for the better pharmaceutical care of RD patients the training of pharmacists
to proper use of professional sources of information should be usefully.
PB  - Elsevier
C3  - Value in Health
T1  - Sources of information and pharmacists' knowledge regarding rare diseases and orphan drugs: cross-sectional study in Serbia
VL  - 17
IS  - 7
SP  - A542
EP  - A542
DO  - 10.1016/j.jval.2014.08.1747
ER  - 

@conference{
author = "Arsić, J. and Krajnović, Dušanka and Tasić, Ljiljana and Marinković, Valentina and Đorđević, J.",
year = "2014",
abstract = "Objectives: The lack of information and scientific knowledge of rare diseases (RDs)
and orphan drug (ODs) could affect the quality of health care delivered to patients suf-
fering from rare diseases. The aim of this study was evaluation of the level of the general
epidemiological knowledge among pharmacists regarding RDs and ODs as well as how
that knowledge is influenced by information sources, education level and years of expe-
rience. MethOds: The research design was based on a descriptive cross-sectional study.
A questionnaire previously used in a pilot KAP study in Serbiain2012 was applied. The
respondents were 182 pharmacists from public pharmacies in seven of 29 districts in
Serbia. Individual level of knowledge was assessed by total number of correct answers
from a maximum of 9, and overall knowledge was an average of the individual level of
knowledge. Results: In total, 155 pharmacists were included in the full analysis set
(response rate was 86.3%). Overall, the mean age was 43.4 years, and 94% were women.
The average number of information sources regarding RD was 1.7%, and mostly one
source out of five was used (56.1%). Pharmacists who were engaged in post-graduate
programmes or completed such programmes tended to use more sources of information
(69.2%) than those who were not involved in any such programme (41.9%). The mean
value of correct answers about pharmacists’ knowledge regarding RD and OD was 4 ±
1.77. Most pharmacists (n = 30, 19.35%) replied correctly to 6 questions. cOnclusiOns:
The results indicate that years of experience and age among pharmacists do not have
influence to the overall knowledge about RD. The positive impact of education was evi-
dently, and for the better pharmaceutical care of RD patients the training of pharmacists
to proper use of professional sources of information should be usefully.",
publisher = "Elsevier",
journal = "Value in Health",
title = "Sources of information and pharmacists' knowledge regarding rare diseases and orphan drugs: cross-sectional study in Serbia",
volume = "17",
number = "7",
pages = "A542-A542",
doi = "10.1016/j.jval.2014.08.1747"
}

Arsić, J., Krajnović, D., Tasić, L., Marinković, V.,& Đorđević, J.. (2014). Sources of information and pharmacists' knowledge regarding rare diseases and orphan drugs: cross-sectional study in Serbia. in Value in Health
Elsevier., 17(7), A542-A542.
https://doi.org/10.1016/j.jval.2014.08.1747

Arsić J, Krajnović D, Tasić L, Marinković V, Đorđević J. Sources of information and pharmacists' knowledge regarding rare diseases and orphan drugs: cross-sectional study in Serbia. in Value in Health. 2014;17(7):A542-A542.
doi:10.1016/j.jval.2014.08.1747 .

Arsić, J., Krajnović, Dušanka, Tasić, Ljiljana, Marinković, Valentina, Đorđević, J., "Sources of information and pharmacists' knowledge regarding rare diseases and orphan drugs: cross-sectional study in Serbia" in Value in Health, 17, no. 7 (2014):A542-A542,
https://doi.org/10.1016/j.jval.2014.08.1747 . .